|WHAT DOES IT MEAN FOR YOU?|
| Cost for In-Warranty
Medtronic offers a $499Δ pump for you to own.Tandem offers a $9993 pump that must be returned within 30 days of your existing warranty end date.
|Programs for Out-of-Warranty Animas® Customer||YesΩ||No3||Medtronic will seek insurance coverage for your new pump and offers a $500 trade-in credit for your out-of-warranty Animas® pump.Ω
Customers can obtain the CGM starter kit for $300 out-of-pocket or for $100 with CGM trade-in.β
We wanted to say a special thank you to Animas® and its customers.
The MiniMed™ 670G system offers two levels of SmartGuard™ technology — the Auto Mode and Suspend before low features.
SmartGuard™ Auto Mode‡
SmartGuard™ Suspend before low§
Animas® decided to close their insulin pump business in October 2017. Animas® selected Medtronic as the partner of choice, because of our rich 30-year history of innovation and service. Medtronic has supported over 1.2 million people living with diabetes around the world. Medtronic customers have access to 24-hour technical support, supply reorder services, and dedicated global customer support. Our unparalleled service is the #1 reason that people with diabetes stay with Medtronic.
Both Animas® and Medtronic have stopped selling Animas® supplies. If you have run out of supplies and you are interested in transitioning to a Medtronic product, call 800-646-4633, ext. 21055.
If your insulin pump is out of warranty, Animas® will no longer provide service or a replacement. This means you are at risk of going off therapy and back to multiple daily injections should anything happen to your Animas® pump.
Call Medtronic at 800-646-4633, ext. 21055 today to discuss your options and ensure you do not experience a disruption in therapy.
While the Animas Exchange Program has expired, Medtronic still has options available. You may be able to take advantage of our Switch2System program for $499*.
Call Medtronic at 800-646-4633, ext. 21055 to learn more about the Switch2System.
* See terms and conditions for the Switch2System at https://www.medtronicdiabetes.com/products/device-upgrading
If your in-warranty pump malfunctions, please call Animas® at 877-937-7867 for assistance.
Please call Animas® at 877-937-7867 for assistance.
1. Bergenstal R, Garg S, Weinzimer S, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316(13):1407–1408.
2. dQ&A. (2017) dQ&A Patient Panel, Q4 2016, Summary Report.
3. https://www.tandemdiabetes.com/products/animas-pump-return-program. Accessed September 19, 2019.
* Refers to SmartGuard™ Auto Mode feature; The MiniMed™ 670G system can automatically increase or decrease insulin delivery based on continuous glucose monitoring (CGM) values; however, the user must still administer meal boluses. ADA recommendation for a glucose range is 80-180 mg/dL in non-pregnant adults with diabetes. Individual results may vary.
# Based on Guardian™ Sensor 3 glucose values.
β A discounted cash option of $300 for a CGM starter kit is available if you are still in-warranty with your current CGM system or don’t have CGM insurance coverage. Discounted pricing on a CGM Starter Kit requires the return of your current CGM transmitter. A CGM Starter Kit includes transmitter and one box of sensors.
Ω Up to $500 credit in exchange for your current out-of-warranty Animas® insulin pump. Patient must return their Animas pump to Medtronic to obtain the credit. Medtronic will offer a self-addressed pre-paid envelope to return your Animas® pump.
∆ Restrictions apply. Programs available to qualified customers with a valid prescription. Cost may vary based on warranty status, program eligibility and insurance coverage. Program terms and conditions are subject to change at any time and without notice. https://www.medtronicdiabetes.com/products/device-upgrading. Accessed September 19, 2019.
§ WARNING: Do not use the Suspend on low feature to prevent or treat low glucose. Always confirm your sensor glucose reading using your BG meter, and follow the instructions of your healthcare professional to treat low glucose. Using Suspend on low alone to prevent or treat low glucose may result in prolonged hypoglycemia.
‡ WARNING: Do not use Auto Mode for a period of time after giving a manual injection of insulin by syringe or pen. Manual injections are not accounted for in Auto Mode. Therefore, Auto Mode could deliver too much insulin. Too much insulin may cause hypoglycemia. Consult with your healthcare professional for how long you need to wait after a manual injection of insulin before you resume Auto Mode.
Important Safety Information: MiniMed™ 630G System with SmartGuard™ technology
Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. MiniMed™ 630G system is approved for ages 14 years or older with Guardian™ Sensor 3 and MiniMed™ 630G system is approved for ages 16 years or older with Enlite™ sensor. Both systems require a prescription. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR®NEXT LINK 2.4 meter is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK 2.4 meter, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed™ 630G or MiniMed™ 530G system are not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.
WARNING: The SmartGuard™ Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard feature, it is important to read the SmartGuard™ feature information in the User Guide and discuss proper use of the feature with your healthcare provider.
Important Safety Information: MiniMed™ 670G System
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.
The Medtronic MiniMed™ 670G System consists of the following devices: MiniMed™ 670G Insulin Pump, the Guardian™ Link (3) Transmitter, the Guardian™ Sensor (3), One-press Serter, and the CONTOUR® NEXT Link 2.4 Glucose Meter. The system requires a prescription.
The Guardian™ Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian™ Sensor (3).
WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library
For additional information, please consult the appropriate User Guide.
© Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.